trazodone has been researched along with Depression, Involutional in 48 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 6.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| "In view of the possibility that her auditory hallucinations began after starting trazodone, trazodone was discontinued, leading to a complete resolution of her auditory hallucinations." | 5.40 | Auditory hallucinations induced by trazodone. ( Hatano, K; Ishii, N; Shiotsuki, I; Terao, T, 2014) |
| " The most frequent adverse events (AEs) were dizziness and somnolence in the trazodone group, and nausea and headache in the venlafaxine group." | 2.94 | A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. ( Albert, U; Cattaneo, A; Comandini, A; Di Dato, G; Di Loreto, G; Fagiolini, A; Ferrando, L; Herman, E; Kasper, S; Muntean, C; Olivieri, L; Pálová, E; Salvatori, E; Tongiani, S, 2020) |
| " The majority of the adverse reactions of trazodone were mild to moderate, and the most frequent adverse reactions (≥5%) were dizziness, dry mouth, somnolence, and nausea." | 2.79 | Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial. ( Cao, Y; Chen, DC; Cheng, ZH; Cui, LJ; Li, LH; Shi, JG; Tan, QR; Wang, G; Xie, WW; Xu, XF; Zhang, HG; Zhang, KR; Zhang, L; Zhao, JP; Zheng, HB, 2014) |
| " There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events." | 2.76 | A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. ( Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C, 2011) |
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 2.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| "In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence." | 2.73 | Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? ( Andreescu, C; Buysse, DJ; Cyranowski, JM; Dombrovski, AY; Frank, E; Houck, PR; Mallinger, AG; Mulsant, BH; Thase, ME, 2008) |
| "Trazodone is a serotonin antagonist and reuptake inhibitor approved for the treatment of major depressive disorder." | 2.72 | Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. ( Albert, U; Lamba, P; Stahl, SM, 2021) |
| "Trazodone has been reported to be an effective hypnotic for patients with antidepressant-associated insomnia." | 2.71 | The effects of trazodone on sleep in patients treated with stimulant antidepressants. ( Gözükirmizi, E; Guilleminault, C; Kaynak, D; Kaynak, H, 2004) |
| "Treatment of major depressive disorder aims for symptom remission and recovery of function, and involves a multifaceted approach including drug therapy, evidence-based psychotherapy, and electroconvulsive therapy, according to disease severity." | 2.53 | Practical guidance for prescribing trazodone extended-release in major depression. ( Coluccia, A; Cuomo, A; De Giorgi, R; Fagiolini, A; Forgione, RN; Goracci, A, 2016) |
| "Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs)." | 2.48 | Rediscovering trazodone for the treatment of major depressive disorder. ( Catena Dell'Osso, M; Comandini, A; Fagiolini, A; Kasper, S, 2012) |
| "Trazodone is an antidepressant of the serotonin (5-HT2) antagonist and reuptake inhibitor class, and has been considered to act as a multifunctional drug." | 2.46 | [Trazodone--its multifunctional mechanism of action and clinical use]. ( Frecska, E, 2010) |
| "Trazodone is an approved antidepressant drug for adults and has shown efficacy on symptoms like anxiety and insomnia observed in AUD patients as well." | 1.91 | Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone. ( Di Nicola, M; Janiri, L; Moccia, L; Panaccione, I; Pepe, M; Sani, G, 2023) |
| "Trazodone was discontinued, and his symptoms resolved within a week." | 1.72 | Trazodone-induced parkinsonism: A case report. ( Colangelo, T; Mills, A; Sharma, KD, 2022) |
| " A previously verified physiologically-based pharmacokinetic model based on in vitro and in vivo information on trazodone pharmacokinetics was applied, aiming at predicting brain receptor occupancy (RO) after single and repeated dosing of the IR formulation and repeated dosing of the OAD formulation in healthy subjects." | 1.72 | Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations. ( Comandini, A; Di Dato, G; Jones, HM; Ke, AB; Mangano, G; McFeely, S; Oggianu, L; Rosignoli, MT, 2022) |
| " After experiencing a major Covid-19-related personal trauma, patients showed clinical worsening which required dosage adjustment (20 mg/day vortioxetine; 600 mg/day trazodone, and 200 mg/day sertraline) and, for some of them, hospitalisation." | 1.72 | Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma. ( Amici, E; De Filippis, S; Di Giovanni, A; Giovanetti, V; Kotzalidis, GD; Lombardozzi, G; Matrone, M; Perrini, F; Trovini, G, 2022) |
| "Trazodone has been recently found to inhibit 7-dehydrocholesterol reductase and alter sterol concentrations in rodents, cell culture, human fibroblasts, and blood." | 1.72 | Desmosterol and 7-dehydrocholesterol concentrations in post mortem brains of depressed people: The role of trazodone. ( Brown, ES; Cenik, B; Cenik, C; McDonald, JG; Palka, JM; Tamminga, CA; Thompson, BM, 2022) |
| "Trazodone hydrochloride is an antidepressant medicine that affects the chemical messengers in the brain known as neurotransmitters, which include acetylcholine, norepinephrine, dopamine, and serotonin." | 1.72 | Attempting to Increase the Effectiveness of the Antidepressant Trazodone Hydrochloride Drug Using π-Acceptors. ( Alamri, A; Alamri, AS; Alhabeeb, AA; Alhomrani, M; Alkhatabi, HA; Alsanie, WF; Alyami, H; Felimban, RI; Gaber, A; Habeeballah, H; Raafat, BM; Refat, MS; Shakya, S, 2022) |
| "Neuropathic pain is a chronic debilitating condition caused by injury or disease of the nerves of the somatosensory system." | 1.62 | Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain. ( Amato, A; Di Giorgio, FP; di Matteo, A; Durando, L; Garrone, B; Milanese, C; Pistillo, L; Tongiani, S, 2021) |
| "Priapism is a serious urological and a medical emergency which has often been associated with psychotropic medications (including the antidepressant trazodone), use of marijuana and alcohol, and other factors." | 1.43 | Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse? ( Khan, QS; Lokhande, A; Tucker, P, 2016) |
| "In view of the possibility that her auditory hallucinations began after starting trazodone, trazodone was discontinued, leading to a complete resolution of her auditory hallucinations." | 1.40 | Auditory hallucinations induced by trazodone. ( Hatano, K; Ishii, N; Shiotsuki, I; Terao, T, 2014) |
| " Greater clinical severity and low initial dosing may increase the risk of switching antidepressants." | 1.35 | Antidepressant switching among adherent patients treated for depression. ( Hassan, M; Marcus, SC; Olfson, M, 2009) |
| " Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging." | 1.32 | The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. ( Buysse, DJ; Cassella, J; Mendelson, WB; Meyer, RE; Roehrs, T; Roth, T; Walsh, JK; Woods, JH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 4 (8.33) | 18.2507 |
| 2000's | 17 (35.42) | 29.6817 |
| 2010's | 16 (33.33) | 24.3611 |
| 2020's | 10 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, KD | 1 |
| Colangelo, T | 1 |
| Mills, A | 1 |
| Oggianu, L | 1 |
| Di Dato, G | 2 |
| Mangano, G | 1 |
| Rosignoli, MT | 1 |
| McFeely, S | 1 |
| Ke, AB | 1 |
| Jones, HM | 1 |
| Comandini, A | 3 |
| De Filippis, S | 1 |
| Lombardozzi, G | 1 |
| Matrone, M | 1 |
| Amici, E | 1 |
| Trovini, G | 1 |
| Perrini, F | 1 |
| Di Giovanni, A | 1 |
| Giovanetti, V | 1 |
| Kotzalidis, GD | 1 |
| Cenik, B | 1 |
| Palka, JM | 1 |
| Thompson, BM | 1 |
| McDonald, JG | 1 |
| Tamminga, CA | 1 |
| Cenik, C | 1 |
| Brown, ES | 1 |
| Pawar, MA | 1 |
| Shevalkar, GB | 1 |
| Vavia, PR | 1 |
| Alsanie, WF | 1 |
| Alhomrani, M | 1 |
| Alamri, AS | 1 |
| Alyami, H | 1 |
| Shakya, S | 1 |
| Habeeballah, H | 1 |
| Alkhatabi, HA | 1 |
| Felimban, RI | 1 |
| Alamri, A | 1 |
| Alhabeeb, AA | 1 |
| Raafat, BM | 1 |
| Refat, MS | 1 |
| Gaber, A | 1 |
| Di Nicola, M | 1 |
| Pepe, M | 1 |
| Panaccione, I | 1 |
| Moccia, L | 1 |
| Janiri, L | 1 |
| Sani, G | 1 |
| Fagiolini, A | 3 |
| Albert, U | 2 |
| Ferrando, L | 1 |
| Herman, E | 1 |
| Muntean, C | 1 |
| Pálová, E | 1 |
| Cattaneo, A | 1 |
| Di Loreto, G | 3 |
| Olivieri, L | 3 |
| Salvatori, E | 1 |
| Tongiani, S | 2 |
| Kasper, S | 3 |
| Garrone, B | 1 |
| di Matteo, A | 1 |
| Amato, A | 1 |
| Pistillo, L | 1 |
| Durando, L | 1 |
| Milanese, C | 1 |
| Di Giorgio, FP | 1 |
| Lamba, P | 1 |
| Stahl, SM | 1 |
| Buoli, M | 1 |
| Rovera, C | 1 |
| Pozzoli, SM | 1 |
| Fiorentini, A | 1 |
| Cremaschi, L | 1 |
| Caldiroli, A | 1 |
| Altamura, AC | 1 |
| Khan, QS | 1 |
| Tucker, P | 1 |
| Lokhande, A | 1 |
| Chen, HM | 1 |
| Yang, YH | 1 |
| Chen, KJ | 1 |
| Lee, Y | 1 |
| McIntyre, RS | 1 |
| Lu, ML | 1 |
| Lee, YC | 1 |
| Hsieh, MC | 1 |
| Chen, VC | 1 |
| Osváth, P | 1 |
| Shiotsuki, I | 1 |
| Terao, T | 1 |
| Ishii, N | 1 |
| Hatano, K | 1 |
| Zhang, L | 1 |
| Xie, WW | 1 |
| Li, LH | 1 |
| Zhang, HG | 1 |
| Wang, G | 1 |
| Chen, DC | 1 |
| Cao, Y | 1 |
| Cui, LJ | 1 |
| Zhang, KR | 1 |
| Shi, JG | 1 |
| Tan, QR | 1 |
| Zheng, HB | 1 |
| Xu, XF | 1 |
| Cheng, ZH | 1 |
| Zhao, JP | 1 |
| Goracci, A | 1 |
| Forgione, RN | 1 |
| De Giorgi, R | 1 |
| Coluccia, A | 1 |
| Cuomo, A | 1 |
| Treviño, LA | 1 |
| Ruble, MW | 1 |
| Treviño, K | 1 |
| Weinstein, LM | 1 |
| Gresky, DP | 1 |
| Dombrovski, AY | 1 |
| Cyranowski, JM | 1 |
| Mulsant, BH | 1 |
| Houck, PR | 1 |
| Buysse, DJ | 2 |
| Andreescu, C | 1 |
| Thase, ME | 1 |
| Mallinger, AG | 1 |
| Frank, E | 1 |
| Marcus, SC | 1 |
| Hassan, M | 1 |
| Olfson, M | 1 |
| Sheehan, DV | 1 |
| Rozova, A | 1 |
| Gossen, ER | 1 |
| Gibertini, M | 1 |
| Liu, PY | 1 |
| Tzeng, NS | 1 |
| Frecska, E | 1 |
| Li, TC | 1 |
| Su, PY | 1 |
| Chiu, HW | 1 |
| Peng, CH | 1 |
| Sánchez-Romero, A | 1 |
| Mayordomo-Aranda, A | 1 |
| García-Delgado, R | 1 |
| Durán-Quintana, JA | 1 |
| Fang, Y | 1 |
| Yuan, C | 1 |
| Xu, Y | 1 |
| Chen, J | 1 |
| Wu, Z | 1 |
| Cao, L | 1 |
| Yi, Z | 1 |
| Hong, W | 1 |
| Wang, Y | 1 |
| Jiang, K | 1 |
| Cui, X | 1 |
| Calabrese, JR | 1 |
| Gao, K | 1 |
| Chen, HC | 1 |
| Tsai, SJ | 1 |
| Shamseddeen, W | 1 |
| Clarke, G | 1 |
| Keller, MB | 1 |
| Wagner, KD | 1 |
| Birmaher, B | 1 |
| Emslie, GJ | 1 |
| Ryan, N | 1 |
| Asarnow, JR | 1 |
| Porta, G | 1 |
| Brent, DA | 1 |
| Catena Dell'Osso, M | 1 |
| Becker, PM | 1 |
| Kaynak, H | 1 |
| Kaynak, D | 1 |
| Gözükirmizi, E | 1 |
| Guilleminault, C | 1 |
| Passmore, MJ | 1 |
| Devarajan, S | 1 |
| Ghatavi, K | 1 |
| Gardner, DM | 1 |
| Kutcher, SP | 1 |
| Mendelson, WB | 1 |
| Roth, T | 1 |
| Cassella, J | 1 |
| Roehrs, T | 1 |
| Walsh, JK | 1 |
| Woods, JH | 1 |
| Meyer, RE | 1 |
| Almási, J | 1 |
| Rihmer, Z | 1 |
| Lam, RW | 1 |
| Kennedy, SH | 1 |
| Mizoguchi, Y | 1 |
| Monji, A | 1 |
| Dionisio, P | 2 |
| Munizza, C | 1 |
| Rachid, F | 1 |
| Golaz, J | 1 |
| Bondolfi, G | 1 |
| Bertschy, G | 1 |
| Papakostas, GI | 2 |
| Fava, M | 1 |
| Stein, DJ | 1 |
| Hemmings, S | 1 |
| Moolman-Smook, H | 1 |
| Audenaert, K | 1 |
| Shelton, RC | 1 |
| Maes, M | 2 |
| Westenberg, H | 1 |
| Vandoolaeghe, E | 2 |
| Demedts, P | 1 |
| Wauters, A | 1 |
| Neels, H | 1 |
| Meltzer, HY | 1 |
| Verkerk, R | 1 |
| Lin, A | 1 |
| Scharpé, S | 1 |
| Shen, H | 1 |
| Awata, S | 1 |
| Konno, M | 1 |
| Sato, M | 1 |
| Tesler-Mabe, CS | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Loeb, C | 1 |
| Roccatagliatà, G | 1 |
| Besio, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maintenance Psychotherapies in Recurrent Depression: Study II[NCT00227981] | 93 participants | Interventional | 1995-03-31 | Completed | |||
| Bipolar Disorder and Oxidative Stress Injury Mechanism - Clinical Big Data Analysis Based on Machine Learning[NCT03949218] | 3,702 participants (Actual) | Observational | 2018-11-20 | Completed | |||
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for trazodone and Depression, Involutional
| Article | Year |
|---|---|
Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action.
Topics: Depressive Disorder, Major; Drug Administration Schedule; Humans; Selective Serotonin Reuptake Inhib | 2021 |
[Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-G | 2013 |
Practical guidance for prescribing trazodone extended-release in major depression.
Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Delayed-Action Preparations; Depressive Dis | 2016 |
[Trazodone--its multifunctional mechanism of action and clinical use].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; | 2010 |
Rediscovering trazodone for the treatment of major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; H | 2012 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 2004 |
Using metaanalysis to evaluate evidence: practical tips and traps.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Major; Doub | 2005 |
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Maj | 2008 |
12 trials available for trazodone and Depression, Involutional
| Article | Year |
|---|---|
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depr | 2020 |
Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antidepressive Agents; Clomipramine; | 2019 |
Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, M | 2014 |
Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?
Topics: Adult; Affect; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major | 2008 |
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Delayed-Action Prepa | 2009 |
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Topics: Buspirone; China; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Co | 2011 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 | 2012 |
The effects of trazodone on sleep in patients treated with stimulant antidepressants.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Electromyography; Electr | 2004 |
A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
Topics: Adult; Aged; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; H | 2005 |
A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; | 2006 |
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Rel | 1997 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
27 other studies available for trazodone and Depression, Involutional
| Article | Year |
|---|---|
Trazodone-induced parkinsonism: A case report.
Topics: Activities of Daily Living; Aged; Depressive Disorder, Major; Humans; Male; Parkinsonian Disorders; | 2022 |
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations.
Topics: Antidepressive Agents; Brain; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Trazo | 2022 |
Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.
Topics: Adult; Antidepressive Agents; COVID-19; Depressive Disorder, Major; Double-Blind Method; Female; Hum | 2022 |
Desmosterol and 7-dehydrocholesterol concentrations in post mortem brains of depressed people: The role of trazodone.
Topics: Brain; Dehydrocholesterols; Depressive Disorder, Major; Desmosterol; Humans; Trazodone | 2022 |
Design and Development of Gastro-retentive Drug Delivery System for Trazodone Hydrochloride: a Promising Alternative to Innovator's Controlled-Release Tablet.
Topics: Animals; Delayed-Action Preparations; Depressive Disorder, Major; Rabbits; Solubility; Tablets; Traz | 2022 |
Attempting to Increase the Effectiveness of the Antidepressant Trazodone Hydrochloride Drug Using π-Acceptors.
Topics: Acetylcholine; Antidepressive Agents; Depressive Disorder, Major; Dopamine; Humans; Ligands; Molecul | 2022 |
Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone.
Topics: Adult; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Humans; Quality o | 2023 |
Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Depressive Disorder, Major; Disease Models, Animal; Drug S | 2021 |
Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse?
Topics: Adrenergic alpha-1 Receptor Antagonists; Depressive Disorder, Major; Hepatitis C; Humans; Male; Midd | 2016 |
Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cohort Studies; Co | 2019 |
Auditory hallucinations induced by trazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Hallucinations; | 2014 |
Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, | 2017 |
Antidepressant switching among adherent patients treated for depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Dep | 2009 |
Low-dose trazodone-related drug eruption.
Topics: Adult; Depressive Disorder, Major; Drug Eruptions; Humans; Male; Trazodone | 2010 |
Trazodone ameliorates nightmares in major depressive disorder.
Topics: Depressive Disorder, Major; Dreams; Humans; Male; Trazodone; Young Adult | 2011 |
Probable interaction between trazodone and carbamazepine.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Carbamazepine; De | 2011 |
Trazodone-induced severe headache.
Topics: Adult; Anti-Anxiety Agents; Depressive Disorder, Major; Headache; Humans; Male; Sleep Initiation and | 2011 |
Trazodone as a hypnotic in major depression.
Topics: Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Trazodone | 2004 |
Serotonin syndrome with prolonged dysphagia.
Topics: Aged; Deglutition Disorders; Depressive Disorder, Major; Female; Humans; Selective Serotonin Reuptak | 2004 |
The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder, Major; Dose-Response | 2004 |
Low-dose-trazodone-induced disorganized type psychosis.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Psychia | 2005 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
5-HT2A: its role in frontally mediated executive function and related psychopathology.
Topics: Attitude; Cognition Disorders; Depressive Disorder, Major; Frontal Lobe; Humans; Male; Positron-Emis | 2007 |
A lasting change in trazodone response after non-convulsive electroshock therapy for medication-resistant senile depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Majo | 1998 |
Acute dystonic reaction with trazodone.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Comb | 1998 |
Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Bupropion; Depressive Disorde | 2000 |
[Variations in the urinary level of MHPG in depressive syndromes].
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Anxiety; Depression; Depressive Disorder | 1979 |